Ultralife Stock Price, News & Analysis

Ultralife (NASDAQ: ULBI) has scheduled its fourth quarter 2024 financial results release for March 11, 2025, before market opening. The delayed reporting timeline, later than the company's usual practice of reporting in the sixth week after year-end, is attributed to additional time needed to complete the accounting close and audit of Electrochem Solutions, Inc., which was acquired on October 31, 2024.

Management will host an investor conference call and webcast at 8:30 AM ET on the same day. Participants joining by phone must pre-register through a provided link to ensure reliable connection. A live webcast will be available on the company's website, with a replay accessible shortly after the call.

Ultralife (NASDAQ: ULBI) has announced two key executive appointments effective January 6, 2025. Jeffrey Luke joins as Chief Marketing Officer, tasked with reframing corporate and brand strategies while ensuring global alignment. Luke brings over 20 years of B2B marketing experience across various industries.

James Pope has been appointed Senior Vice President - Sales & Business Development, Battery & Energy Products, bringing 37 years of battery and power industry experience. Pope will focus on market expansion and aligning global sales efforts to maximize revenue and build strategic partnerships.

CEO Mike Manna emphasized these appointments are important for commercializing transformational products and executing the company's long-term growth strategy. The expanded leadership team aims to enhance new product development, strengthen customer relationships, and capitalize on growth opportunities.

Ultralife (NASDAQ:ULBI) has announced its participation in The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference. The event is scheduled for Wednesday, December 11th, 2024 at the New York Athletic Club in New York City.

The conference provides a unique platform for emerging growth and dynamic publicly traded companies to connect with institutional and individual investors in an exclusive one-on-one format. Throughout the day, Ultralife will engage in direct meetings with investors and analysts. Interested parties can schedule meetings through the provided registration link.

Ultralife (NASDAQ: ULBI) reported Q3 2024 results with sales of $35.7 million, down from $39.5 million in Q3 2023. The Battery & Energy Products segment saw 1.9% growth, while Communications Systems sales decreased 58.2%. Gross profit was $8.7 million (24.3% margin), compared to $9.8 million (24.8%) last year. Operating income decreased to $0.5 million from $2.1 million, including $0.3 million in acquisition-related costs. GAAP EPS fell to $0.02 from $0.08. The company reduced debt by $4.1 million to $8.0 million, representing a 68.2% reduction over two quarters.

Ultralife (NASDAQ: ULBI) has completed the acquisition of Electrochem Solutions for $50.0 million in cash from Integer Holdings Based in Raynham, MA, Electrochem specializes in primary lithium metal and ultracapacitor cells and battery packs, serving energy, military, and environmental markets globally. The acquired company generated revenue of $34 million for the trailing twelve months ended September 30, 2024. The transaction was financed through a new Credit and Security Agreement with KeyBank, N.A., M&T Bank, and Community Bank as lenders.

Ultralife (NASDAQ: ULBI) has scheduled its third quarter 2024 financial results release for November 8, 2024, before market opens. The delayed reporting accommodates the anticipated closing of Electrochem Solutions acquisition by end of October. Management will host an investor conference call and webcast at 8:30 AM ET on the same day. Pre-registration is required for phone participants through a provided link. A live webcast will be available on the company's website, with a replay accessible shortly after the call.

Ultralife (NASDAQ: ULBI) has signed a stock purchase agreement to acquire Electrochem Solutions, Inc. for $50.0 million in cash from Integer Holdings (NYSE: ITGR). The acquisition is expected to close by the end of October 2024 and be accretive on an EPS basis for 2025.

Electrochem, based in Raynham, MA, designs and manufactures primary lithium metal and ultracapacitor cells and battery packs for various markets. For the trailing twelve-month period ended June 30, 2024, Electrochem recorded revenue of $34 million.

The acquisition aligns with Ultralife's strategy to increase operating leverage through scale and manufacturing efficiencies. It brings a complementary customer base, technical resources, and product portfolio, creating opportunities for revenue growth, cross-selling, and gross margin expansion.

Ultralife (NASDAQ: ULBI) reported strong Q2 2024 results, with sales reaching $43.0 million, up from $42.7 million in Q2 2023. The Battery & Energy Products segment achieved record-high sales, growing 8.3%. Gross profit increased to $11.6 million (26.9% of revenue), compared to $10.6 million (24.8%) in Q2 2023. Operating income rose 6.9% to $3.9 million. GAAP EPS was $0.18, down from $0.21 in Q2 2023, which included a $0.07 per share Employee Retention Credit. The company reported an Adjusted EBITDA of $5.4 million (12.6% of sales) and a backlog of $93.0 million. Notably, Ultralife reduced its debt by 52.2% to $12.1 million.

Ultralife (NASDAQ: ULBI) will release its second quarter results for the period ending June 30, 2024, on July 25, 2024, before market open.

Management will host an investor conference call and webcast at 8:30 AM ET on the same day. Participants are required to pre-register for the call to ensure a smooth connection.

A live webcast will be available on the company's investor website, with a replay accessible shortly after the live broadcast.